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With its approval in 2007 for advanced hepatocellular carci-
noma (HCC), sorafenib became the ﬁrst systemic agent with pro-
ven activity against the disease. To date, two large randomized
studies in advanced stage HCC (BCLC C and a subset of BCLC B)
have demonstrated its anti-cancer activity and ability to extend
survival in patients with Childs A cirrhosis [1,2]. Since then, sev-
eral studies have been launched to evaluate sorafenib’s potential
role in less advanced HCC. Uniquely, sorafenib’s ability to
improve survival is not mediated by inducing signiﬁcant tumor
shrinkage, but by its ability to slow progression and prolong
the time to tumor progression (TTP). While some data has been
presented [3], several ongoing studies including the SPACE
(NCT00855218) and STORM (NCT0692770) studies are evaluating
sorafenib as an adjuvant (after deﬁnitive therapy) to transarterial
chemoembolization (TACE) and curative resection or radiofre-
quency ablation (RFA), respectively. The current study by Vitale
and colleagues uses a cost–beneﬁt analysis to determine the
potential utility of using sorafenib in the neo-adjuvant setting,
prior to liver transplant [4]. The clinical need to ask this question
is real, as the authors highlight, drop-out from HCC progression
beyond Milan criteria is one of the main reasons why patients
awaiting transplant for HCC do not receive an organ.
The Milan criteria was initially described by Mazzaferro and
colleagues over a decade ago and has served as the benchmark
for prioritizing patients with HCC and otherwise lower MELD
scores [5]. However, even with priority, there is still a relative
shortage of livers available and HCC patients are competing with
those with decompensated liver disease for organs. Though there
are regional differences for wait times, the optimal managementJournal of Hepatology 20
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from prospective studies and our natural inclination is ‘‘to do
something’’ when a patient has a known malignancy. Retrospec-
tive analyses do suggest that locoregional therapies such as TACE
and RFA may be effective ‘‘bridge therapies’’ to transplant [6,7];
the basic notion being that existing lesions can be kept within
size criteria with these approaches. A recent consensus confer-
ence on transplant and HCC endorsed this concept, especially
when wait times are greater than 6 months [8]. However, these
modalities fail as they do not prevent the development of metas-
tases or the development of new, de novo HCC in a cirrhotic liver.
To determine the potential utility of sorafenib while awaiting
transplant, the authors of this manuscript develop a Markov
model based on the hazard ratio for sorafenib to decrease the risk
of progression in the two studies in advanced HCC [1,2]. The
model compared the use of sorafenib as a bridging therapy for
patients with well-compensated liver disease and HCC to no
bridging therapy unless wait times were greater than 6 months,
when loco-regional therapies were taken into account. The study
assessed sorafenib’s neo-adjuvant use on survival as measured by
quality-adjusted life days, transplant probability, costs, willing-
ness to pay, and net health beneﬁt. Using a HR of 0.47 for inter-
mediate stage HCC (BCLC B) derived in a subset analysis of the
SHARP study, the authors found that with a monthly drop out
probability of 5% and median time to transplant of 3 months,
the gain in liver transplant probability due to sorafenib was 5%
and increased with length of waiting time and decreasing hazard
ratio. These data are shown in Fig. 1 adapted from the manu-
script. Additionally, the models demonstrated a median survival
beneﬁt of 94 quality adjusted life days (QALDs) for sorafenib,
and the net health beneﬁt was 37 QALDs. Net health beneﬁt
was sensitive to not only waiting time (>6 months), but also
the effectiveness of other (locoregional) therapies. This is an
important challenge to the conclusions of the study as in many
centers wait times are a year or longer and in that case, patients
are surely being treated with a locoregional therapy – the beneﬁt
of which (e.g. HR), if any, is unknown. Further, while subset anal-
yses from randomized studies in advanced disease found that the
HR for sorafenib in BCLC B patients was less than for BCLC C
patients (i.e. those with earlier stage derived a greater beneﬁt),
we do not know that this is the case for patients with tumor
staged within Milan criteria where the true HR is unknown.
Given the challenge of facing a patient with potentially curable
HCC and a clear wait time of >6 months, treating physicians offer12 vol. 56 j 723–725
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Fig. 1. Adapted from [4].
International Hepatologypatients locoregional therapy while waiting, so why not offer
them sorafenib in addition or even instead?
While the work by Vitale is of interest and highlights an area
of unmet medical need, besides the true efﬁcacy (HR) of sorafenib
in this setting, the main issues to prevent its routine use is the
lack of available safety data in this population. Drugs with anti-
angiogenic activity have been associated with surgical complica-
tions such as bleeding and delayed wound healing when used in
the perioperative setting [9]. In the renal carcinoma literature,
neoadjuvant sorafenib speciﬁcally has not been associated with
surgical complications when stopped at least one day before sur-
gery [10,11]. However, there are concerns unique to liver trans-
plantation such as vascular anastomoses, liver regeneration,
and graft rejection. A recent laboratory study evaluated the
effects of sorafenib on liver regeneration in a mouse model
[12]. Mice were treated in 3 groups; group 1 received sorafenib
for 14 days until the day prior to hepatectomy, group 2 received
sorafenib as group one and continued after surgery, and group 3
received it only after surgery. The study demonstrated that when
sorafenib was stopped one day before surgery there were no
effects on liver regeneration, however, there was a decrease in
liver regeneration in the other two groups. While these data
and the urology literatures are reassuring, at the current time
there is a lack of safety data to recommend the use of sorafenib
in the pre-transplant setting. Importantly, unlike in the case of
elective surgery where the last dose of sorafenib can be con-
trolled, the nature of liver transplant makes this timing difﬁcult
and convincing safety data needs to be generated with sorafenib
in the pre-transplant setting, speciﬁcally in regards to when
sorafenib should be stopped. Sorafenib is an oral agent generally
given twice daily. In a Phase I study of patients with preserved
liver function, the half-life ranged from 24 to 38 h [13] and does
not appear to be altered in cases of liver dysfunction [14]. Con-
ceivably, if a patient’s tumor is controlled, sorafenib exposure
in the pre-transplant period could be minimized by discontinuing
drug at a pre-speciﬁed MELD score when the chance of being
called for transplant becomes more likely. Based on the available724 Journal of Hepatology 201data, a minimum of 24 h would be desired, but longer would be
preferred. In addition, pre-clinical models have demonstrated an
acceleration in the development of metastasis in mouse models
after short-term exposure to VEGF receptor tyrosine kinase inhib-
itors [15]. This theoretical possibility of actually promoting recur-
rence is concerning and would need to be assessed prospectively.
In reality, wait times for most patients with HCC are
>6 months and many are treated with locoregional therapy
despite the lack of prospective randomized data supporting its
use in this setting. There is currently a double-blind multi-center
Phase III study comparing TACE and placebo versus TACE plus
sorafenib in patients with HCC before liver transplant (HeiLivCa)
[16]. Results from this study should help clinicians better under-
stand the risk and beneﬁts of using sorafenib in this setting. How-
ever, for patients that are not candidates for loco-regional
therapy, there should not be a tendency to use sorafenib alone
as a bridge therapy at this time.
Ultimately, we hope to move beyond anatomic stage for the
selection of patients with HCC for transplant. More molecular
studies are needed to identify and validate prognostic markers
of favorable clinical behavior. In addition, the identiﬁcation of
predictive markers for those patients that are most likely to ben-
eﬁt from a management strategy that includes sorafenib is
needed.Conﬂict of interest
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